Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

US FDA approves Natco Pharma's anti-cancer drug azacitidine

The approved product is a generic version of Vidaza, which recorded annual sales of $ 188 mn

BS B2B Bureau  |  Hyderabad 

US FDA approves Natco Pharma's anti-cancer drug azacitidine

Limited has received final approval from the US Food and Drug Administration (FDA) for injection used in the treatment of cancer. “Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US for for injection, 100 mg per vial, single-dose vial - a generic version of by Celgene Corporation,” said the company in a press release.

Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.

is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). generated total combined sales of $ 188 million for the twelve-month period ending April, 2017, based on industry sales data.

First Published: Tue, June 27 2017. 15:02 IST
RECOMMENDED FOR YOU

US FDA approves Natco Pharma's anti-cancer drug azacitidine

The approved product is a generic version of Vidaza, which recorded annual sales of $ 188 mn

The approved product is a generic version of Vidaza, which recorded annual sales of $ 188 mn
Limited has received final approval from the US Food and Drug Administration (FDA) for injection used in the treatment of cancer. “Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US for for injection, 100 mg per vial, single-dose vial - a generic version of by Celgene Corporation,” said the company in a press release.

Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.

is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). generated total combined sales of $ 188 million for the twelve-month period ending April, 2017, based on industry sales data.

image
Business Standard
177 22

US FDA approves Natco Pharma's anti-cancer drug azacitidine

The approved product is a generic version of Vidaza, which recorded annual sales of $ 188 mn

Limited has received final approval from the US Food and Drug Administration (FDA) for injection used in the treatment of cancer. “Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US for for injection, 100 mg per vial, single-dose vial - a generic version of by Celgene Corporation,” said the company in a press release.

Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.

is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). generated total combined sales of $ 188 million for the twelve-month period ending April, 2017, based on industry sales data.

image
Business Standard
177 22